Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)

BACKGROUND: Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized phase II trial to examine the clinical utility and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Susumu, Kubota, Kaoru, Sugawara, Shunichi, Teramukai, Satoshi, Noro, Rintaro, Fujikawa, Kei, Hirose, Takashi, Atagi, Shinji, Minami, Seigo, Iida, Shinichiro, Kuraishi, Hiroshi, Aiba, Tomoiki, Minegishi, Yuji, Matsumoto, Masaru, Seike, Masahiro, Gemma, Akihiko, Kawahara, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166935/
https://www.ncbi.nlm.nih.gov/pubmed/36807519
http://dx.doi.org/10.1002/cam4.5652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166935/
https://www.ncbi.nlm.nih.gov/pubmed/36807519
http://dx.doi.org/10.1002/cam4.5652

Ejemplares similares